scholarly journals A randomized, controlled, two-month pilot trial of stannous fluoride dentifrice versus sodium fluoride dentifrice after oxalate treatment for dentinal hypersensitivity

2020 ◽  
Vol 24 (11) ◽  
pp. 4043-4049
Author(s):  
Chad J. Anderson ◽  
Gerard Kugel ◽  
Yuanshu Zou ◽  
Marco Ferrari ◽  
Robert Gerlach
Keyword(s):  
Sodium Fluoride ◽  
Pilot Trial ◽  
Potassium Oxalate ◽  
Double Blind ◽  
Randomized Controlled ◽  
Stannous Fluoride ◽  
Fluoride Dentifrice ◽  
Professional Treatment ◽  
Dentinal Hypersensitivity ◽  
At Home

Abstract Objectives To compare the effects of a stannous fluoride dentifrice and a sodium fluoride dentifrice on dentinal hypersensitivity when used with an oxalate-based regimen combining in-office and at-home treatment. Materials and methods In this single-center, randomized, controlled, double-blind, pilot clinical trial, 30 subjects were professionally treated at baseline with a 3% oxalate/potassium salt solution on up to two target teeth, then randomized 1:1 to either 0.454% stannous fluoride or 0.243% sodium fluoride overlabeled dentifrice. Both groups were given 6 sensitivity strips (3.14% potassium oxalate gel) and a soft, manual toothbrush. Subjects were permitted to apply strips on up to two teeth, up to three times per tooth, at home as desired throughout the study. Dentinal sensitivity (cold air blast challenge) was assessed at baseline, immediately after post-professional treatment, and at day 60 using the Schiff scale and a Visual Analog Scale (VAS). Results Immediately after professional oxalate treatment, the overall mean Schiff and VAS score decreased 25.6% and 22.4% from baseline, respectively (p ≤ 0.001 for both). At day 60, further reductions in both mean scores were seen in both groups. There were no significant differences between the groups at day 60. All treatments were well tolerated. Conclusions In subjects treated with oxalates for dentinal hypersensitivity, both stannous fluoride and sodium fluoride dentifrices are well tolerated, are feasible for routine use, and do not detract from the desensitizing effects of an in-office and at-home oxalate combination treatment regimen. Clinical relevance Either stannous fluoride or sodium fluoride dentifrices can be recommended to dentinal hypersensitivity patients who undergo professional oxalate treatment.

A Clinical Assessment of the Efficacy of a Stannous-Containing Sodium Fluoride Dentifrice on Dentinal Hypersensitivity

2010 ◽  
Vol 11 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Tao He ◽  
Trevor Day ◽  
Johannes Einwag ◽  
Joachim S. Hermann ◽  
Mary Kay Anastasia ◽  
...  
Keyword(s):  
Sodium Fluoride ◽  
Clinical Assessment ◽  
Negative Control ◽  
Control Group ◽  
Lower Sensitivity ◽  
Double Blind ◽  
Parallel Group ◽  
Sensitive Teeth ◽  
Fluoride Dentifrice ◽  
Dentinal Hypersensitivity

Abstract Aim To measure the desensitizing benefits of an experimental stannous-containing sodium fluoride dentifrice versus a regular sodium fluoride negative control. Methods and Materials This study was a randomized, double-blind, parallel group, fourweek clinical trial. Subjects reporting dentinal hypersensitivity were enrolled and randomized to the experimental dentifrice or the control dentifrice to use twice daily for four weeks. Efficacy assessments (Air Blast) were performed at baseline and weeks two and four. Separate analyses were performed for the two most sensitive teeth at baseline and for all 12 teeth. Results for weeks two and four combined also were analyzed. Results Thirty-one subjects were included in the analyses. For the two most sensitive teeth, the experimental dentifrice showed statistically significantly less sensitivity (p<0.05) versus the control at weeks two and four and for weeks two and four combined. The sensitivity reduction ranged from 24.9% to 28.4% over the control. For all 12 teeth, the experimental group had statistically significantly (p<0.03) lower sensitivity scores versus the control group at week two and weeks two and four combined. Conclusion The experimental dentifrice demonstrated significant desensitizing advantages versus the control. Clinical Significance This stannouscontaining sodium fluoride dentifrice provides an effective treatment for patients with dentinal hypersensitivity, significantly reducing sensitivity versus a negative control in this four-week trial. Citation Day TN, Einwag J, Hermann JS, He T, Anastasia MK, Barker M, Zhang Y. A Clinical Assessment of the Efficacy of a Stannous- Containing Sodium Fluoride Dentifrice on Dentinal Hypersensitivity. J Contemp Dent Pract [Internet]. 2010 Jan; 11(1):001-008. Available from:http://www.thejcdp.com/journal/view/volume11- issue1-day.

Efficacy and Safety of a Novel Stabilized Stannous Fluoride and Sodium Hexametaphosphate Dentifrice for Dental Hypersensitivity

2006 ◽  
Vol 7 (2) ◽  
pp. 1-8 ◽  
Author(s):  
Thomas Schiff ◽  
Tao He ◽  
Lisa Sagel ◽  
Robert Baker
Keyword(s):  
Sodium Fluoride ◽  
Sodium Hexametaphosphate ◽  
Control Group ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Sensitivity Score ◽  
Stannous Fluoride ◽  
Air Index ◽  
The Mean ◽  
Dentinal Hypersensitivity

Abstract Purpose Dentinal hypersensitivity is a common complaint among dental patients. Recently, a novel 0.454% stabilized stannous fluoride dentifrice containing sodium hexametaphosphate (SHMP) was introduced that offers a desensitizing benefit. This trial was conducted to assess the desensitizing efficacy of this new dentifrice relative to a sodium fluoride control dentifrice. Methods and Materials This was a double-blind, parallel-group, randomized clinical trial conducted according to the American Dental Association (ADA) Guidelines for the Acceptance of Products for the Treatment of Dentinal Hypersensitivity. Ninety subjects who met the entrance criteria were stratified based on age, gender, and baseline sensitivity scores and randomly assigned to either the stabilized stannous fluoride + SHMP dentifrice (Crest® Pro-Health) or the sodium fluoride control dentifrice. Subjects were instructed to brush twice daily for eight weeks. Efficacy assessments were made, including tactile (Yeaple probe) and thermal (Schiff Air Index) sensitivity, and an oral soft tissue examination was conducted at baseline, week four, and week eight. Results The mean sensitivity score based on the Schiff Air Index for the stannous fluoride + SHMP group was statistically significantly lower than that of the control group, at both weeks four and eight (P < .0001). At week eight, the stannous fluoride + SHMP dentifrice group had an adjusted mean 44% lower than that of the control group. The mean tactile sensitivity score for the stannous fluoride + SHMP group was statistically significantly higher, indicating a reduction in sensitivity, than that of the control group, at both weeks four and eight (P < .0001). At week eight, the stannous fluoride + SHMP dentifrice group had a mean desensitizing improvement of 71% greater than the control. Conclusion The stabilized stannous fluoride + SHMP dentifrice provided statistically significant reductions in dentinal hypersensitivity at four and eight weeks compared to the sodium fluoride control dentifrice. Citation Schiff T, He T, Sagel L, Baker R. Efficacy and Safety of a Novel Stabilized Stannous Fluoride and Sodium Hexametaphosphate Dentifrice for Dentinal Hypersensitivity. J Contemp Dent Pract 2006 May;(7)2:001-008.

scholarly journals Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A Randomized Controlled Trial in Healthy Adults

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2066
Author(s):  
Oliver Chen ◽  
Traci M. Blonquist ◽  
Eunice Mah ◽  
Kristen Sanoshy ◽  
Dawn Beckman ◽  
...  
Keyword(s):  
Clinical Laboratory ◽  
Controlled Trial ◽  
Vital Signs ◽  
Healthy Adults ◽  
Double Blind ◽  
Safety Measures ◽  
Randomized Controlled ◽  
Gastrointestinal Tolerability ◽  
Blood And Urine Samples ◽  
At Home

Nutritional ketosis is a state of mildly elevated blood ketone concentrations resulting from dietary changes (e.g., fasting or reduced carbohydrate intake) or exogenous ketone consumption. In this study, we determined the tolerability and safety of a novel exogenous ketone diester, bis-hexanoyl-(R)-1,3-butanediol (BH-BD), in a 28-day, randomized, double-blind, placebo-controlled, parallel trial (NCT04707989). Healthy adults (n = 59, mean (SD), age: 42.8 (13.4) y, body mass index: 27.8 (3.9) kg/m2) were randomized to consume a beverage containing 12.5 g (Days 0–7) and 25 g (Days 7–28) of BH-BD or a taste-matched placebo daily with breakfast. Tolerability, stimulation, and sedation were assessed daily by standardized questionnaires, and blood and urine samples were collected at Days 0, 7, 14, and 28 for safety assessment. There were no differences in at-home composite systemic and gastrointestinal tolerability scores between BH-BD and placebo at any time in the study, or in acute tolerability measured 1-h post-consumption in-clinic. Weekly at-home composite tolerability scores did not change when BH-BD servings were doubled. At-home scores for stimulation and sedation did not differ between groups. BH-BD significantly increased blood ketone concentrations 1-h post-consumption. No clinically meaningful changes in safety measures including vital signs and clinical laboratory measurements were detected within or between groups. These results support the overall tolerability and safety of consumption of up to 25 g/day BH-BD.

scholarly journals Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial

2014 ◽  
Vol 22 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Miranda A.L. van Tilburg ◽  
Olafur S. Palsson ◽  
Yehuda Ringel ◽  
William E. Whitehead
Keyword(s):  
Irritable Bowel Syndrome ◽  
Pilot Trial ◽  
Double Blind ◽  
Randomized Controlled ◽  
Irritable Bowel

scholarly journals Synbiotic therapy decreases microbial translocation and inflammation and improves immunological status in HIV-infected patients: a double-blind randomized controlled pilot trial

2012 ◽  
Vol 11 (1) ◽  
Author(s):  
Luz A González-Hernández ◽  
Luis F Jave-Suarez ◽  
Mary Fafutis-Morris ◽  
Karina E Montes-Salcedo ◽  
Luis G Valle-Gutierrez ◽  
...  
Keyword(s):  
Pilot Trial ◽  
Microbial Translocation ◽  
Double Blind ◽  
Immunological Status ◽  
Randomized Controlled

Bosentan for mild pulmonary vascular disease in Asd patients (the BOMPA trial): a double-blind, randomized controlled, pilot trial

2013 ◽  
Vol 168 (5) ◽  
pp. 5081-5082 ◽  
Author(s):  
Alexander Van De Bruaene ◽  
Katrijn Jansen ◽  
Pieter De Meester ◽  
Marion Delcroix ◽  
Jens-Uwe Voigt ◽  
...  
Keyword(s):  
Vascular Disease ◽  
Pilot Trial ◽  
Pulmonary Vascular Disease ◽  
Double Blind ◽  
Randomized Controlled

scholarly journals Dentin Tubular Occlusion with Bioactive Glass Containing Dentrifice and Gluma Desensitizer–A Comparative Sem Evaluation

2014 ◽  
Vol 02 (01) ◽  
pp. 016-021
Author(s):  
Ashu Gupta ◽  
Neha Sharma ◽  
Manmohan Bramta
Keyword(s):  
Bioactive Glass ◽  
Treatment Modalities ◽  
Tooth Surface ◽  
Strontium Chloride ◽  
Potassium Oxalate ◽  
Dentinal Tubules ◽  
Initial Application ◽  
Desensitizing Agents ◽  
Dentinal Hypersensitivity ◽  
At Home

AbstractDentinal hypersensitivity (DH) is a painful clinical condition and is characterized by pain arising from exposed dentin in response to various stimuli. Various treatment modalities are available to treat dentinal hypersensitivity which include at-home and in-office treatment. At home treatment generally consists of a variety of dentrifices containing different constituents like stannous fluoride, strontium chloride and potassium oxalate. These agents cause occlusion of dentinal tubules which decreases both dentine permeability and fluid movement thereby reducing hypersensitivity. Recently, bioactive glass (NovaMin) has been incorporated as a remineralising ingredient in dentifrice formulations for treating Dentinal Hyprsensitivity. It relieves the symptoms by precipitating hydroxycarbonate apatite (HCA) onto the tooth surface. Another combination product consisting of an aqueous solution of 5% glutaraldehyde and 35% hydroxyethyl methacrylate (Gluma desensitizer) has also been reported to be an effective desensitizing agent. Thus, the aim of the study was to evaluate and compare the tubule occluding effect of of two desensitizing agents, which are bioactive glass (Novamin), and Gluma Desensitizer. In the present study bioactive glass was found to produce more completely occluded tubules while Gluma desensitizer caused more partial occlusion on initial application. Hence, NovaMin application could be more effective in providing relief from dentinal hypersensitivity when compared with Gluma Desensitizer.

Sign in / Sign up

Export Citation Format

Share Document